Ask AI
ProCE Banner Activity

Incorporating Immune Checkpoint Inhibitors Into Practice for Advanced Urothelial Cancer: Expert Perspectives From the USA (Podcast Pearls)

PDF
Experts from the USA provide their thoughts on recent advances with immune checkpoint therapy for advanced urothelial carcinoma.

Released: March 19, 2021

Share

Supporters

Supported by an educational grant from

Pfizer and EMD Serono

Faculty Disclosure

Primary Author

Petros Grivas, MD, PhD

Professor, Division of Hematology Oncology
Department of Medicine
Medical Director, International Program
Medical Director, Local/Regional Outreach
University of Washington
Professor, Clinical Research Division
Fred Hutchinson Cancer Center
Seattle, Washington

Jonathan Rosenberg, MD

Attending Physician, Chief
Genitourinary Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York